US 2023/0027475 A1Published application

Anti-oncolytic virus antigen antibodies and methods of using same

AssigneesAdmare Therapeutics Society, Provincial Health Services Authority, UVic Industry Partnerships Inc.

InventorsEmma J. Cummins, Jan Peter Bergqvist, Brad Nelson, Kwame Twumasi-Boateng, Yin Yu Eunice Kwok, Julian Smazynski, Francois Benard, Julie Marie Rousseau, Kuo-Shyan Lin

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

Provided are antibodies that specifically bind Vaccinia Virus (VV) A56 or B5 antigen. Also provided are fusion proteins and conjugates that comprise the antibodies. Pharmaceutical compositions and kits that comprise the antibodies, fusion proteins and conjugates are also provided. Aspects of the present disclosure further include methods of using the antibodies, fusion proteins and conjugates, e.g., for therapeutic purposes. In certain embodiments, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual having cancer, wherein the individual comprises cancer cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cancer cells by VV antigens expressed on the surface of the infected cancer cells. Aspects of the present disclosure further include methods of targeting an antibody, fusion protein, or conjugate that specifically binds an oncolytic virus (OV) antigen to cancer cells in an individual.

Claims139

Dependent claims

An antibody that specifically binds to Vaccinia Virus A56 antigen (VV A56) and competes for binding to VV A56 with an antibody comprising:

a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence SSYWIC (SEQ ID NO:
3),
a VH CDR2 comprising the amino acid sequence CIYAGSGGSTYYATWAKG (SEQ ID NO:
4), and
a VH CDR3 comprising the amino acid sequence AYSDRSGGYSFNL (SEQ ID NO:
5);
and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence QASQSVDNNNYLA (SEQ ID NO:
6),
a VL CDR2 comprising the amino acid sequence SASSLAS (SEQ ID NO:
7), and
a VL CDR3 comprising the amino acid sequence LGSYDCSDADCYA (SEQ ID NO:
8);
a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence DIYYIS (SEQ ID NO:
11),
a VH CDR2 comprising the amino acid sequence CTYAGSSGSTYYATWAKG (SEQ ID NO:
12), and
a VH CDR3 comprising the amino acid sequence DRYPGTSGRVYGMDL (SEQ ID NO:
13);
and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence QASQSISDLLS (SEQ ID NO:
14),
a VL CDR2 comprising the amino acid sequence SASTLAS (SEQ ID NO:
15), and
a VL CDR3 comprising the amino acid sequence QCNYYSPTYGNG (SEQ ID NO:
16);
a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence SSYWLC (SEQ ID NO:
19),
a VH CDR2 comprising the amino acid sequence CIYNGDGSTHYASWAKG (SEQ ID NO:
20), and
a VH CDR3 comprising the amino acid sequence DYTYNFYTYGFNL (SEQ ID NO:
21);
and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence QASQSVNIWAS (SEQ ID NO:
22),
a VL CDR2 comprising the amino acid sequence KASTLAS (SEQ ID NO:
23), and
a VL CDR3 comprising the amino acid sequence QGGYPSSSSGWA (SEQ ID NO:
24);
or
a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence SSYWIC (SEQ ID NO:
27),
a VH CDR2 comprising the amino acid sequence CTYNGDGSTHYASWAKG (SEQ ID NO:
28), and
a VH CDR3 comprising the amino acid sequence DYTDAFYTYGFNL (SEQ ID NO:
29);
and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence QASQSTSSYLA (SEQ ID NO:
30),
a VL CDR2 comprising the amino acid sequence RASSLAS (SEQ ID NO:
31), and
a VL CDR3 comprising the amino acid sequence QTGFYGSSGHT (SEQ ID NO:
32).

58 more elements

An antibody that specifically binds to Vaccinia Virus B5 antigen (VV B5) and competes for binding to VV B5 with an antibody comprising:

a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence SSYYMC (SEQ ID NO:
35),
a VH CDR2 comprising the amino acid sequence CIYTSSGSAYYANWAKG (SEQ ID NO:
36), and
a VH CDR3 comprising the amino acid sequence NAVGSSYYLYL (SEQ ID NO:
37);
and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence QASQSVAGNNYLS (SEQ ID NO:
38),
a VL CDR2 comprising the amino acid sequence SVSTLAS (SEQ ID NO:
39), and
a VL CDR3 comprising the amino acid sequence QGYYNDGIWA (SEQ ID NO:
40);
or
a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence SYWMC (SEQ ID NO:
43),
a VH CDR2 comprising the amino acid sequence CIYGGSSGSTYYSNWAKG (SEQ ID NO:
44), and
a VH CDR3 comprising the amino acid sequence DGSTWDYFRL (SEQ ID NO:
45);
and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence QASQSINTNYLS (SEQ ID NO:
46),
a VL CDR2 comprising the amino acid sequence QASTLES (SEQ ID NO:
47), and
a VL CDR3 comprising the amino acid sequence QGYYTVENIGNP (SEQ ID NO:
48).

28 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/642,089Filed 11 Sep 2020
Priority: 13 Sep 2019
Published: 26 Jan 2023
Term ends: Not estimatedThe source records don’t support an estimate.

Classification27 codes

C07K 16/081
Against material from viruses: dNA viruses
A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]